Atalanta Therapeutics is a biotechnology company developing treatments for intractable diseases of the central nervous system using RNA interference. Atalanta’s unique platform of divalent small interfering RNA (di-siRNA) enables durable, selective gene silencing throughout the brain and spinal cord in preclinical studies. In January 2025, Atalanta announced the completion of a $97 million Series B financing to support Phase 1 clinical trials of the company’s investigational RNAi therapies for KCNT1-related epilepsy and Huntington’s disease. The company is diligently progressing these programs toward IND submissions this year so that Phase 1 trials can commence and reach patients who are waiting.
MassBio Member Spotlight: Atalanta Therapeutics
Location: Boston, MA
Website: atalantatx.com
Leadership: Alicia Secor, MBA (President & CEO); Aimee L. Jackson, Ph.D. (CSO); and Serena Hung, M.C. (CMO)
Therapeutic area(s): Huntington’s disease, genetic epilepsy, severe chronic pain, and other neurological diseases